The Key Players in Global Type 2 Diabetes Market 2016-2020

Thursday 31 March 2016, Amsterdam

The report, now available on ASDReports, recognizes the following companies as the key players in the Global Type 2 Diabetes Market: AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, and Sanofi SA.

Other Prominent Vendors in the market are: Adocia, Akros Pharma, Amgen, Astellas Pharma, Biocon, Boehringer Ingelheim, Chipscreen Biosciences, ConjuChem, CymaBay Therapeutics, Daiichi Sankyo, DiaMedica, Diasome Pharmaceuticals, Dong-A ST, Elcelyx Therapeutics, Exsulin, Generex, Genfit, Hanmi, Hua Medicine, InteKrin Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Japan Tobacco, Kadmon, KinDex Pharmaceuticals, Kissei, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Ligand, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Novartis, NGM Bio, NuSirt Biopharma, Oramed, Peptron, Pfizer, PhaseBio, Poxel, Sanwa Kagaku Kenkyusho, Sirona Biochem, Takeda, Theracos, Theratechnologies, Transition Therapeutics, VeroScience, vTv Therapeutics, and XBiotech.

Commenting on the report, an analyst said: “The growing awareness of type 2 diabetes and the treatments available for it, as a result of national and global initiatives, drives the market. The increase in the diabetic population has increased accessibility to disease monitoring and disease management devices, and key vendors have begun to focus on emerging markets such as China.”

According to the report, obesity, unhealthy diets, and lack of physical activity have increased the number of diabetes cases worldwide. As reported by WHO, it was estimated that 9% of the adults who are 18 years and above had diabetes in 2014. It was also reported that the global prevalence of diabetes would be around 366 million by 2030. In 2013, nearly 21 million live births were affected by diabetes during pregnancy. An increase in the exposure to the risk factors for type 2 diabetes in low- and middle-income groups is increasing in Middle East, North Africa, Southeast Asian, and Western Pacific regions.

Further, the report states that low diagnosis rate impedes people from availing the treatment, posing a challenge for the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.